CLDX — Celldex Therapeutics, Inc.

Is CLDX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of October 3, 2026

Celldex Therapeutics, Inc. (CLDX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $31.65. The rating moved from Overbought to Neutral on October 2, 2026.

AI analysis

Celldex Therapeutics, Inc. (CLDX) is exposed to the typical binary outcomes of clinical-stage biotechnology: upside tied to positive trial readouts, partnerships or late-stage validation, and downside from clinical or regulatory setbacks and funding dilution. Current market conditions are risk-off, which historically suppresses appetite for smaller biotech issuers and can limit near-term share appreciation. Offsetting this, favorable late-stage biologics news across the sector can lift sentiment for companies with credible development programs. Key near-term drivers to monitor are any announced clinical data timelines, partnering or licensing activity, cash runway updates, and commentary on pricing/access given ongoing Medicare negotiation pressures. Given limited public financial disclosures in the supplied data and elevated policy/market risk, the stock is best approached with caution and close monitoring of upcoming catalysts.

Key factors

  • Macroeconomic risk-off sentiment limits near-term upside for small/mid-cap biotech names and reduces IPO and funding appetite.
  • Pipeline- and trial-driven business model: valuation and near-term moves are likely to be determined by upcoming clinical readouts, regulatory milestones, or partnering activity.
  • Sector tailwind from late-stage biologics and rare-disease successes that can boost investor appetite for validated therapeutic platforms and durable outcomes.
  • Ongoing policy pressure (Medicare drug-price negotiation and broader payer scrutiny) increases potential pricing pressure for high-cost specialty therapies.
  • Absence of recent company filings/EDGAR comparisons in the provided data increases uncertainty around current cash runway, revenue trajectory, and near-term financing needs.
  • Relative illiquidity and headline sensitivity typical of clinical-stage biotechs — share price can move sharply on binary news (trial data, approvals, partnerships).

Risks

  • Binary clinical trial failure or disappointing clinical data that would materially reduce commercial prospects and share value.
  • Regulatory setbacks or longer-than-expected approval timelines that delay potential revenue generation.
  • Price and access pressure from Medicare negotiation and payer cost-containment initiatives that could compress peak pricing and market uptake for novel therapies.
  • Dilution risk if the company needs to raise capital; unfavorable financing conditions in a risk-off market can increase share issuance at depressed prices.
  • Competitive threats from larger pharma entrants or more advanced programs targeting the same indications.
  • Market-wide risk-off flows and geopolitical headlines that can reduce liquidity and amplify downward share moves independent of company fundamentals.

See today's live rating, score and targets

Members see the live hourly rating for CLDX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.